Aricept: Enhance Cognitive Function in Alzheimer's Disease
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.30 (0%) | 🛒 Add to cart |
| 90 | $0.70 | $70.95 $62.78 (12%) | 🛒 Add to cart |
| 120 | $0.66 | $94.60 $79.12 (16%) | 🛒 Add to cart |
| 180 | $0.62 | $141.90 $110.94 (22%) | 🛒 Add to cart |
| 270 | $0.59 | $212.85 $159.10 (25%) | 🛒 Add to cart |
| 360 | $0.57
Best per pill | $283.80 $205.54 (28%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.77 | $46.44 (0%) | 🛒 Add to cart |
| 90 | $0.72 | $69.66 $64.50 (7%) | 🛒 Add to cart |
| 120 | $0.70 | $92.88 $83.42 (10%) | 🛒 Add to cart |
| 180 | $0.66 | $139.32 $119.54 (14%) | 🛒 Add to cart |
| 270 | $0.65 | $208.98 $174.58 (16%) | 🛒 Add to cart |
| 360 | $0.63
Best per pill | $278.64 $227.04 (19%) | 🛒 Add to cart |
Synonyms
| |||
Aricept (donepezil hydrochloride) is a prescription medication specifically formulated for the treatment of dementia related to Alzheimer’s disease. As a centrally acting reversible acetylcholinesterase inhibitor, it works by increasing the concentration of acetylcholine in the brain, a neurotransmitter critical for memory, learning, and cognitive processing. This medication is indicated for mild, moderate, and severe Alzheimer’s disease and is supported by extensive clinical research demonstrating its efficacy in stabilizing or improving cognitive and global function. Proper diagnosis and ongoing medical supervision are essential for optimal therapeutic outcomes.
Features
- Active ingredient: Donepezil hydrochloride
- Available in 5 mg and 10 mg film-coated tablets
- Once-daily oral dosing for patient convenience
- FDA-approved for all stages of Alzheimer’s disease
- Mechanism: Selective reversible inhibition of acetylcholinesterase
- Bioavailability: ~100% with linear pharmacokinetics
- Half-life: approximately 70 hours, allowing steady-state concentration
- Metabolism: Hepatic via CYP2D6 and CYP3A4 isoenzymes
- Excretion: Primarily renal, with some fecal elimination
Benefits
- Slows the progression of cognitive decline in Alzheimer’s patients
- May improve or maintain activities of daily living and behavior
- Supports enhanced communication and social interaction abilities
- Can delay nursing home placement by sustaining functional independence
- Provides a predictable pharmacokinetic profile for consistent dosing
- Demonstrated efficacy in long-term management of dementia symptoms
Common use
Aricept is primarily prescribed for the symptomatic treatment of Alzheimer’s disease. It is used to address cognitive impairment including memory loss, confusion, and problems with reasoning and thinking. The medication may also help with behavioral symptoms such as apathy, depression, and agitation. Treatment is typically initiated after comprehensive neurological assessment and confirmation of Alzheimer’s diagnosis. While not curative, Aricept aims to maintain cognitive and functional abilities for as long as possible during disease progression.
Dosage and direction
The recommended starting dose is 5 mg administered once daily at bedtime. After 4-6 weeks of treatment, the dose may be increased to 10 mg once daily if well tolerated. Tablets should be swallowed whole with water and may be taken with or without food. For patients with moderate to severe hepatic impairment, careful dose titration is recommended. Renal impairment does not significantly affect pharmacokinetics, but caution is advised in severe cases. Dosage adjustments may be necessary based on individual tolerance and clinical response.
Precautions
Patients should be monitored for gastrointestinal effects including nausea, vomiting, and diarrhea, particularly during dose escalation. Caution is advised in patients with cardiac conduction abnormalities, asthma, or chronic obstructive pulmonary disease. Close supervision is recommended for patients at risk of ulcers or gastrointestinal bleeding. Aricept may cause bladder outflow obstruction and should be used cautiously in patients with urinary retention. Regular assessment of cognitive and functional status is essential throughout treatment.
Contraindications
Aricept is contraindicated in patients with known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients in the formulation. It should not be used in patients with severe liver impairment (Child-Pugh Class C). Concurrent use with other cholinergic agents or anticholinesterase medications is contraindicated. Patients with known genetic deficiencies of CYP2D6 metabolism should avoid use or require careful monitoring.
Possible side effects
Common adverse reactions (≥5%) include nausea, diarrhea, insomnia, fatigue, muscle cramps, vomiting, and anorexia. Less frequent effects (1-5%) include headache, dizziness, syncope, bradycardia, agitation, aggression, and urinary incontinence. Rare but serious side effects (<1%) may include seizures, gastrointestinal bleeding, extrapyramidal symptoms, and sinoatrial or atrioventricular block. Most side effects are dose-dependent and often diminish with continued therapy.
Drug interaction
Aricept may potentiate effects of succinylcholine-type muscle relaxants during anesthesia. Concurrent use with cholinergic agonists (bethanechol) or other cholinesterase inhibitors may produce additive effects. Anticholinergic medications may reduce Aricept’s efficacy. CYP3A4 and CYP2D6 inhibitors (ketoconazole, quinidine) may increase donepezil concentrations. Beta-blockers may enhance bradycardic effects. NSAIDs may increase risk of gastrointestinal bleeding. Always inform healthcare providers of all concomitant medications.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic levels due to the drug’s long half-life. Patients and caregivers should establish routines to support medication adherence.
Overdose
Symptoms of overdose may include severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, seizures, and muscle weakness. In cases of suspected overdose, seek immediate medical attention. General supportive measures should be implemented. Atropine may be used as an antidote, with initial intravenous doses of 1.0 to 2.0 mg, with subsequent dosing based on clinical response. Tertiary anticholinergics such as atropine are preferred over glycopyrrolate.
Storage
Store at room temperature (20-25°C or 68-77°F) in the original container. Protect from light and moisture. Keep tightly closed and out of reach of children. Do not use if the blister pack is damaged or tablets show signs of deterioration. Discard any unused medication properly according to local regulations. Do not flush medications down the toilet or pour into drains unless instructed to do so.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Aricept is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary. Always consult with a physician for proper diagnosis and treatment recommendations. Do not initiate or discontinue medication without medical guidance.
Reviews
Clinical studies demonstrate that Aricept provides statistically significant improvements in cognitive function (ADAS-cog) and global clinical impression compared to placebo. Long-term extension studies suggest sustained benefits in activities of daily living for up to 52 weeks. Many clinicians report observable stabilization of cognitive decline in compliant patients. Some caregivers note improved engagement and reduced behavioral symptoms. However, response varies individually, and not all patients experience measurable benefits. Regular follow-up assessments are crucial for evaluating treatment efficacy.